ATE496045T1 - PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - Google Patents

PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

Info

Publication number
ATE496045T1
ATE496045T1 AT08736964T AT08736964T ATE496045T1 AT E496045 T1 ATE496045 T1 AT E496045T1 AT 08736964 T AT08736964 T AT 08736964T AT 08736964 T AT08736964 T AT 08736964T AT E496045 T1 ATE496045 T1 AT E496045T1
Authority
AT
Austria
Prior art keywords
disorders
kinase
inhibitors
phosphatidylinositol
pyrimidine derivatives
Prior art date
Application number
AT08736964T
Other languages
German (de)
Inventor
Paul Goldsmith
Timothy Hancox
Neil Pegg
Stephen Shuttleworth
Elsa Dechaux
Stephen Price
Jonathan Large
Edward Mcdonald
Original Assignee
Hoffmann La Roche
Cancer Res Inst Royal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707088A external-priority patent/GB0707088D0/en
Priority claimed from GB0707611A external-priority patent/GB0707611D0/en
Application filed by Hoffmann La Roche, Cancer Res Inst Royal filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE496045T1 publication Critical patent/ATE496045T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)

Abstract

The invention provides a pyrimidine compound of formula (I): wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
AT08736964T 2007-04-12 2008-04-14 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE ATE496045T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707088A GB0707088D0 (en) 2007-04-12 2007-04-12 Pharmaceutical compounds
GB0707611A GB0707611D0 (en) 2007-04-19 2007-04-19 Pharmaceutical compounds
PCT/GB2008/001301 WO2008125839A2 (en) 2007-04-12 2008-04-14 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase

Publications (1)

Publication Number Publication Date
ATE496045T1 true ATE496045T1 (en) 2011-02-15

Family

ID=39832798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08736964T ATE496045T1 (en) 2007-04-12 2008-04-14 PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

Country Status (13)

Country Link
US (1) US20100130496A1 (en)
EP (1) EP2150546B1 (en)
JP (1) JP2010523639A (en)
KR (1) KR20100016433A (en)
CN (1) CN101765597A (en)
AT (1) ATE496045T1 (en)
AU (1) AU2008237721A1 (en)
BR (1) BRPI0810641A2 (en)
CA (1) CA2683624A1 (en)
DE (1) DE602008004650D1 (en)
IL (1) IL201365A0 (en)
MX (1) MX2009010886A (en)
WO (1) WO2008125839A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008237715A1 (en) * 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2010014939A1 (en) 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
US8507491B2 (en) * 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
RU2011137399A (en) 2009-02-12 2013-03-20 Астеллас Фарма Инк. HETEROCYCLIC DERIVATIVE
RU2515541C2 (en) 2009-11-12 2014-05-10 Ф.Хоффманн-Ля Рош Аг N-7 substituted purines and pyrazolopyrimidines, compositions thereof and methods for use
EP2498780B1 (en) 2009-11-12 2016-09-07 F.Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AU2011290189B8 (en) 2010-08-10 2015-02-19 Astellas Pharma Inc. Heterocyclic compound
BR112013006030B1 (en) 2010-09-29 2020-03-17 Intervet International B.V. COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALES OR N-OXIDES AND USE OF THE COMPOUND
TW201500358A (en) 2010-12-16 2015-01-01 Hoffmann La Roche Tricyclic PI3k inhibitor compounds and methods of use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR102038462B1 (en) 2011-12-15 2019-10-31 노파르티스 아게 Use of inhibitors of the activity or function of PI3K
AR090545A1 (en) 2012-03-28 2014-11-19 Intervet Int Bv HETEROARILO COMPOUND WITH AN ACICLIC BRIDGE UNIT
KR20160027218A (en) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 Compositions and methods of obtaining and using endoderm and hepatocyte cells
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
BR112016010568B1 (en) 2013-11-15 2021-09-21 Bayer Cropscience Aktiengesellschaft PROCESS FOR PREPARATION OF A SUBSTITUTED 2-ETHYLAMINOPYRIDINE DERIVATIVE
RU2713179C2 (en) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Antimitotic amides for treating cancer and proliferative diseases
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN110291069A (en) 2016-12-21 2019-09-27 拜耳农作物科学股份公司 The catalytic hydrogenation of nitrile
JP7352284B2 (en) * 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Pyrrolo[2,3-c]pyridine and related analogs as LSD-1 inhibitors
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. Pikfyve kinase inhibitors
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
JP7485701B2 (en) * 2019-06-06 2024-05-16 北京泰徳製薬股▲フン▼有限公司 2,4,6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
WO2021113506A1 (en) 2019-12-04 2021-06-10 Chdi Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
CA3171187A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Inhibitors of ulk1/2 and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186324C (en) * 2000-04-27 2005-01-26 山之内制药株式会社 Condensed heteroaryl derivatives
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
CA2527079A1 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
JP4906715B2 (en) * 2004-05-08 2012-03-28 ニューロジェン・コーポレーション 4,5-disubstituted-2-arylpyrimidines
US7851466B2 (en) * 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
KR20100016433A (en) 2010-02-12
JP2010523639A (en) 2010-07-15
US20100130496A1 (en) 2010-05-27
WO2008125839A3 (en) 2008-12-24
AU2008237721A1 (en) 2008-10-23
BRPI0810641A2 (en) 2019-09-24
EP2150546A2 (en) 2010-02-10
CA2683624A1 (en) 2008-10-23
DE602008004650D1 (en) 2011-03-03
EP2150546B1 (en) 2011-01-19
MX2009010886A (en) 2009-12-14
WO2008125839A2 (en) 2008-10-23
CN101765597A (en) 2010-06-30
IL201365A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
ATE496045T1 (en) PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
MX2009010881A (en) Pharmaceutical compounds.
GB0423653D0 (en) Pharmaceutical compounds
MX2008013578A (en) Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor.
ATE510841T1 (en) THIAZOLIOPYRIMIDINES AND THEIR USE AS PHOSPHATIDYLINOSITOL-3 KINASE INHIBITORS
EA201000090A1 (en) Triple substituted derivatives of pyrimidine for the treatment of proliferative diseases
WO2009053715A8 (en) Thienopyrimidiene derivatives as pi3k inhibitors
EA201000092A1 (en) TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
MX2009010884A (en) 2-morpholin-4-yl-pyrimidines as pi3k inhibitors.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
ATE456565T1 (en) PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS
EA201070167A1 (en) SUBSTITUTED DERIVATIVES INDAZOLA, ACTIVE AS KINASE INHIBITORS
ATE549336T1 (en) HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE AS PROTEIN KINASE INHIBITORS
NZ592925A (en) Substituted pyrimidines for the treatment of diseases such as cancer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EA201000091A1 (en) DERIVATIVES OF MORFOLINOPYRIMIDINE USED IN DISEASES ASSOCIATED WITH mTOR KINASE AND / OR PI3K
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
EA201190158A1 (en) Derivatives of benzofuranyl for use as glucose kinase inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
NO20092737L (en) Substituted pyrazoloquinazoline derivatives, process for their preparation and their use as kinase inhibitors
AU2011269989A8 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
MX2010003927A (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors.
NO20090580L (en) Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
AU2009282962A8 (en) Compounds as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties